Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports-Reference-Cited by-同舟云学术

Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports

Published:2024-07 Issue:8 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precis Oncol

Author:

Zullo Lodovica¹²^ORCID,Castanet Elora³,Maaradji Zineb⁴,Ghigna Maria Rosa⁵,Bonhomme Benjamin⁶^ORCID,Alamé Melissa⁶,Besse Benjamin¹⁷^ORCID,Cousin Sophie³,Aldea Mihaela¹⁷^ORCID

Affiliation:

1. Department of Cancer Medicine, Thoracic Cancer Unit, Gustave Roussy, Villejuif, France

2. Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy

3. Department of Medical Oncology, Institut Bergonié, Bordeaux, France

4. Department of Thoracic Oncology, European Hospital Georges Pompidou, Paris, France

5. Department of Pathology, Gustave Roussy, Villejuif, France

6. Department of Biopathology, Institut Bergonié, Bordeaux, France

7. Paris-Saclay University, Le Kremlin Bicêtre, France

Abstract

We report the first two cases of EGFR exon20ins SCLC, treated with amivantamab and TKIs.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.24.00257

Reference9 articles.

1. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

2. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

3. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

4. Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

5. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes